Contineum Therapeutics (Contineum Therapeutics) Other Long Term Assets : $2.62 Mil (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Contineum Therapeutics Other Long Term Assets?

Contineum Therapeutics's other long-term assets for the quarter that ended in Mar. 2024 was $2.62 Mil.

Contineum Therapeutics's quarterly other long-term assets increased from Sep. 2023 ($0.15 Mil) to Dec. 2023 ($1.28 Mil) and increased from Dec. 2023 ($1.28 Mil) to Mar. 2024 ($2.62 Mil).

Contineum Therapeutics's annual other long-term assets increased from Dec. 2021 ($0.10 Mil) to Dec. 2022 ($0.13 Mil) and increased from Dec. 2022 ($0.13 Mil) to Dec. 2023 ($1.28 Mil).

Contineum Therapeutics Other Long Term Assets Historical Data

The historical data trend for Contineum Therapeutics's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Contineum Therapeutics Other Long Term Assets Chart

Contineum Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Other Long Term Assets

0.10

0.13

1.28

Contineum Therapeutics Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Other Long Term Assets	Get a 7-Day Free Trial			0.13	-	0.15	1.28	2.62

Contineum Therapeutics Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Contineum Therapeutics (Contineum Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Contineum Therapeutics Inc (NAS:CTNM) » Definitions » Other Long Term Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

10578 Science Center Drive, Suite 200, San Diego, CA, USA, 92121

Website

https://www.contineum-tx.com

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Contineum Therapeutics (Contineum Therapeutics) Headlines

From GuruFocus

Contineum Therapeutics Announces Pricing of Initial Public Offering

By GlobeNewswire • 04-05-2024